MarketPulse

EMP-01

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley's Oral MDMA Therapy Shows Promise in Social Anxiety, Outperforming Placebo

AtaiBeckley reports Phase 2a results for EMP-01 oral R-MDMA in social anxiety disorder, showing 49% responder rates and 38% symptom reduction versus 15% on placebo.
ATAIclinical trial resultssocial anxiety disorder
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley Secures FDA Nod for Phase 3 Depression Trial, Eyes 2029 Runway

AtaiBeckley advances psychedelic depression treatment to Phase 3 with $220.7M cash runway through early 2029, plus positive anxiety trial data.
ATAIPhase 3 clinical trialFDA approval